CW August 2004
Volume 13Issue Number 8 August 2004 ISSN 10593802 Minor Adverse Impact on QOL with Letrozole BenefitsIn the MA17 breast cancer trial among postmenopausal women, the benefits of the aromatase inhibitor letrozole (letrozole reduced breast cancer recurrences by 42%) came at the expense of only minor impacts on quality of life. Women in the randomized, placebo-controlled trial received letrozole (2.5 mg qd, Femara, Novartis) or placebo (qd) following 4.6-6 years of treatment with tamoxifen.
Go to Previous Page Go to Next Page Source & Additional Reading 40th Annual Meeting of the American Society of Clinical Oncology where results were presented by Timothy J. Whelan, McMaster University, Hamilton, Ontario, Canada. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW August 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
